|
Gender, n (%)
| | | | |
|
Female
|
174 (42.9)
|
153 (37.9)
|
261 (42.5)
|
247 (40.4)
|
|
Male
|
232 (57.1)
|
251 (62.1)
|
353 (57.5)
|
365 (59.6)
|
|
Mean age, y (range)
|
59.9 (25–86)
|
59.4 (21–82)
|
60.2 (19–86)
|
59.5 (21–82)
|
|
Age group, n (%)
| | | | |
|
<65 y
|
254 (62.6)
|
277 (68.6)
|
376 (61.2)
|
407 (66.5)
|
|
≥65 but <75 y
|
133 (32.8)
|
108 (26.7)
|
199 (32.4)
|
172 (28.1)
|
|
≥75 y
|
19 (4.7)
|
19 (4.7)
|
39 (6.4)
|
33 (5.4)
|
|
Race, n (%)
| | | | |
|
Asian
|
29 (7.1)
|
23 (5.7)
|
51 (8.3)
|
35 (5.7)
|
|
Black
|
14 (3.4)
|
11 (2.7)
|
27 (4.4)
|
16 (2.6)
|
|
White
|
355 (87.4)
|
361 (89.4)
|
523 (85.2)
|
548 (89.5)
|
|
Other
|
8 (2)
|
9 (2.2)
|
13 (2.1)
|
13 (2.1)
|
|
Cancer diagnosis category, n (%)
| |
|
Colon
|
187 (46.1)
|
188 (46.5)
|
302 (49.2)
|
289 (47.2)
|
|
Rectosigmoid
|
95 (23.4)
|
85 (21)
|
136 (22.1)
|
123 (20.1)
|
|
Rectum
|
123 (30.3)
|
129 (31.9)
|
174 (28.3)
|
197 (32.2)
|
|
Other
|
1 (0.2)
|
2 (0.5)
|
2 (0.3)
|
3 (0.5)
|
|
Number of organs with metastasis, n (%)
| | | | |
|
0
|
2 (0.5)
|
2 (0.5)
|
6 (1.0)
|
2 (0.3)
|
|
1
|
237 (58.4)
|
230 (56.9)
|
271 (44.1)
|
256 (41.8)
|
|
>1
|
167 (41.1)
|
172 (42.6)
|
337 (54.9)
|
354 (57.8)
|
|
Metastatic sites, n (%)
| | | | |
|
Liver
|
283 (69.7)
|
294 (72.8)
|
431 (70.2)
|
459 (75.0)
|
|
Lung
|
160 (39.4)
|
152 (37.6)
|
277 (45.1)
|
271 (44.3)
|
|
Lymph
|
88 (21.7)
|
100 (24.8)
|
181 (29.5)
|
173 (28.3)
|
|
Liver metastasis only, n (%)
|
134 (33)
|
141 (34.9)
|
146 (23.8)
|
153 (25.0)
|
|
ECOG performance status, n (%)
| | | | |
|
0
|
314 (77.3)
|
317 (78.5)
|
350 (57.0)
|
349 (57.0)
|
|
1
|
92 (22.7)
|
87 (21.5)
|
250 (40.7)
|
250 (40.8)
|
|
2
|
0
|
0
|
14 (2.3)
|
13 (2.1)
|
|
Prior bevacizumab, n (%)
| | | | |
|
Yes
|
133 (32.8)
|
132 (32.7)
|
187 (30.5)
|
186 (30.4)
|
|
No
|
273 (67.2)
|
272 (67.3)
|
427 (69.5)
|
426 (69.6)
|
